FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC By Ogkologos - June 24, 2026 66 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast02 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Excellence in cancer research nursing: Celebrating innovation during tough times October 7, 2022 Few People with Cancer Undergo Testing for Inherited Gene Mutations August 1, 2023 EMA Recommends Granting a Marketing Authorisation for Decitabine / Cedazuridine August 31, 2023 Coronavirus reports – Part 6 “The kids being home all the... July 17, 2020 Load more HOT NEWS Sing Anyway Seven Extra Years New on NCI Websites for December 2018 New on NCI’s Websites for September 2021
